A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study is being done to learn more about the safety of an investigational drug called ATYR1923, and to find out more about the effects of different doses of this drug on the lungs of people who have pulmonary sarcoidosis. "Investigational" means that it is not approved by the United …
Double-blind, randomized, single-center pilot study to assess the effectiveness of pregabalin (Lyrica) in the management of mucositis pain in head and neck cancer.
The primary purpose of this study is to determine the therapeutic effectiveness of Ifetroban to improve sinus and nasal symptoms and quality of life in subjects with Aspirin Exacerbated Respiratory Disease (AERD).
This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess …
We are currently enrolling participants for a clinical research study to look at the effectiveness and safety of an investigational medication AXS-05 (a combination of bupropion and dextromethorphan) compared to bupropion (Approved by FDA), in patients with depression who have not responded to prior treatment with at least one antidepressant. …
A double-blind placebo controlled trial of high dose hydroxychloroquine (HCQ) as a treatment for COVID-19 positive patients who are quarantined at home
The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.
The PATCH trial tests hydroxychloroquine as a treatment in patients with COVID-19 and a preventative medication in health care workers at high risk of contracting COVID-19.
You are invited to take part in a research study for with the investigational drug, QR-110 (referred to as “the study drug”) for Leber's Congenital Amourosis . Currently there is no approved treatment for LCA10. The study drug is designed to repair the problem that causes LCA10. This may stop …
Please reference protocol section 2.
Congrats! You have your own personal workspace now.